This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Zenith Epigenetics Corp.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of Sanjay Lakhotia
Introduction
Sanjay Lakhotia is a notable inventor based in Orinda, California. He has made significant contributions to the field of cancer treatment, particularly focusing on triple-negative breast cancer (TNBC). His innovative approach combines various therapeutic agents to enhance treatment efficacy.
Latest Patents
Lakhotia holds a patent for a groundbreaking invention titled "Combination therapy for the treatment of triple-negative breast cancer." This invention outlines methods for treating TNBC through the co-administration of a BET bromodomain inhibitor and a second therapeutic agent, such as a PARP inhibitor. The specific compounds involved include 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine and its derivatives.
Career Highlights
Sanjay Lakhotia is currently associated with Zenith Epigenetics Corporation, where he continues to work on innovative cancer therapies. His research and development efforts are aimed at improving treatment outcomes for patients suffering from aggressive forms of breast cancer.
Collaborations
Lakhotia collaborates with esteemed colleagues, including Eric Campeau and Laura M Tsujikawa. Their combined expertise contributes to the advancement of cancer treatment methodologies.
Conclusion
Sanjay Lakhotia's work exemplifies the impact of innovative thinking in the medical field. His contributions to cancer therapy are paving the way for more effective treatments for patients with triple-negative breast cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile